About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Chicago | 15,574 Studies Near You | Clareo Health

Clinical Trials LocationsChicago

Clinical Trials in Chicago

Discover 15,574 clinical trials near Chicago, Illinois. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 8981-9000 of 15,574 trials

COMPLETEDNA2.2 miles

Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients

NCT02759146

The purpose of this study is to compare reflexology to meditative practices to reduce symptoms in cancer patients.

Michigan State University347 participantsStarted May 2016

Tucson, Arizona, United States • Tucson, Arizona, United States • Chicago, Illinois, United States +4 more locations

WITHDRAWNNA2.2 miles

An Educational Intervention to Improve Disease Management Knowledge of Hospitalized Patients With COPD

NCT03323190

The objective of this study is to determine if inpatient COPD education would result in improved patient knowledge of COPD.

Chronic Obstructive Pulmonary DiseasePatient EducationInpatients

Rush University Medical CenterStarted Aug 2016

Chicago, Illinois, United States

COMPLETEDPhase 12.2 miles

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

NCT01482143

The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)

Fragile X Syndrome

Novartis Pharmaceuticals21 participantsStarted Mar 2012

Sacramento, California, United States • Chicago, Illinois, United States • Nashville, Tennessee, United States +1 more locations

Find Trials by Condition in Chicago

Breast Cancerin Chicago Lung Cancerin Chicago Prostate Cancerin Chicago Colorectal Cancerin Chicago Melanomain Chicago Leukemiain Chicago Lymphomain Chicago Pancreatic Cancerin Chicago Ovarian Cancerin Chicago Brain Cancerin Chicago Diabetes

Data from ClinicalTrials.govTerms

UNKNOWNNA21 miles

The STOP-HPV Trial 4: Bundle Intervention

NCT03609242

Most adolescents who receive human papillomavirus (HPV) vaccine are vaccinated in pediatric practices, yet missed opportunities (MOs) for HPV vaccination occur often and lead to low HPV vaccination rates. This cluster randomized clinical trial (RCT) will test the effectiveness (and cost-effectiveness) of HPV vaccine communication, performance feedback reports and provider prompts (the bundle) to reduce MOs and increase HPV vaccination rates.

ImmunizationVaccination

University of California, Los Angeles48 participantsStarted Aug 2018

Itasca, Illinois, United States

COMPLETEDPhase 326 miles

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817

The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.

Post Surgical Ocular Inflammation and Pain

Kala Pharmaceuticals, Inc.520 participantsStarted Jun 2016

Chandler, Arizona, United States • Phoenix, Arizona, United States • Artesia, California, United States +32 more locations

No Longer Available80 miles

PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation

NCT02475798

The purpose of this extended study is to collect confirmatory safety and effectiveness data on the Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the commercially available Atrium iCAST™ covered stent in the treatment of aortoiliac and iliac aneurysms.

Aortoiliac AneurysmsIliac Aneurysms

Cook Research Incorporated

Phoenix, Arizona, United States • Palo Alto, California, United States • Stanford, California, United States +23 more locations

TERMINATEDPhase 2122 miles

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

NCT03573505

The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF). The secondary objectives of this study are: to evaluate the efficacy of BG00011 compared with placebo in participants with IPF as determined by change in percent predicted forced (expiratory) vital capacity (FVC); to assess progression-free survival in participants who receive BG00011 compared with placebo; to assess the occurrence of IPF exacerbation in participants who receive BG00011 compared with placebo; to assess the incidence of absolute decline in FVC ≥10% in participants who receive BG00011 compared with placebo; to assess the time to death or lung transplantation in participants who receive BG00011 compared with placebo, and the transplant-free survival rate at Week 26 and Week 52; to assess the time to non-elective hospitalizations in participants who receive BG00011 compared with placebo; to assess additional pulmonary function test (PFT) findings in participants who receive BG00011 compared with placebo; To assess performance on the 6 minute walk test (6MWT) in participants who receive BG00011 compared with placebo; to evaluate the safety and tolerability of BG00011; and to evaluate the serum concentration of BG00011.

Idiopathic Pulmonary Fibrosis

Biogen109 participantsStarted Sep 2018

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +87 more locations

COMPLETEDPhase 1201 miles

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

NCT01928459

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

Advanced Solid TumorsMetastatic Solid Tumors

Novartis Pharmaceuticals62 participantsStarted Oct 2013

Tampa, Florida, United States • Ann Arbor, Michigan, United States • Detroit, Michigan, United States +19 more locations

COMPLETED237 miles

Evaluation of Biomarkers of Traumatic Brain Injury

NCT01426919

The primary objective of this study is to evaluate the utility of the Banyan UCH-L1/GFAP Detection Assay as an aid in the evaluation of suspected traumatic brain injury (Glasgow Coma Scale score 9-15) in conjunction with other clinical information within 12 hours of injury to assist in determining the need for a CT scan of the head.

Traumatic Brain Injury

Banyan Biomarkers, Inc2,011 participantsStarted Dec 2012

San Diego, California, United States • Hartford, Connecticut, United States • Gainesville, Florida, United States +21 more locations

COMPLETEDNA237 miles

Robotic Bronchoscopy for Peripheral Pulmonary Lesions

NCT03727425

In this study, the feasibility of performing robotic navigation of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions will be evaluated.

Auris Health, Inc.55 participantsStarted Nov 2018

Detroit, Michigan, United States • St Louis, Missouri, United States • Cleveland, Ohio, United States +2 more locations

TERMINATEDPhase 2246 miles

A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)

NCT02553330

A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.

Alopecia Areata

Incyte Corporation90 participantsStarted Nov 2015

Birmingham, Alabama, United States • Hot Springs, Arkansas, United States • New Haven, Connecticut, United States +15 more locations

COMPLETEDPhase 3262 miles

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

NCT01694277

The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.

Gastrointestinal Stromal Tumors

AB Science258 participantsStarted Apr 2012

St Louis, Missouri, United States • Bordeaux, France • Nice, France +2 more locations

COMPLETEDPhase 1355 miles

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT02474537

This is a phase I, multi-center, open-label, single oral dose, parallel group study to evaluate the pharmacokinetics and safety of INC280 in non-cancer subjects with impaired hepatic function and non-cancer subjects with normal hepatic function.The study population will be healthy male and postmenopausal or sterile female subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will be assigned to groups according to their hepatic function: normal (Group 1), mild (Group 2), moderate (Group 3), and severe (Group 4) impairment. This study consists of a two-staged design with interim analysis. In Stage 1, subjects in Groups 1, 2 and 3 will be enrolled. Upon completion of Stage 1, an interim analysis will be conducted. Depending on the results of the analysis, either the study will conclude with no further enrollment or Stage 2 will commence with enrollment of Group 4. A minimum of 6 evaluable subjects per group will be enrolled.Once enrolled in the study, participants will be confined to the facility for 4 days, given a single dose of INC280 and monitored for pharmacokinetic and safety assessments.

Hepatic Impairment

Novartis Pharmaceuticals31 participantsStarted Jun 2015

Miami, Florida, United States • Miami, Florida, United States • Orlando, Florida, United States +2 more locations

COMPLETEDNA412 miles

The CDR Implementation Trial

NCT03162354

To increase the accuracy of doctors' decisions to launch or forgo child abuse evaluations in their young, acutely head-injured patients, investigators have derived and validated a clinical decision rule (CDR) that detects abusive head trauma (AHT) with 96% sensitivity in pediatric intensive care unit (PICU) settings. This "CDR Implementation Trial" across eight PICU sites will assess the CDR's actual impact on AHT screening accuracy, identify factors associated with maximal physician acceptance and application of this novel AHT screening tool, and assess the sustainability of active CDR implementation strategies.

Pediatric Abusive Head Trauma

Milton S. Hershey Medical Center420 participantsStarted Aug 2017

Hartford, Connecticut, United States • Wichita, Kansas, United States • Kansas City, Missouri, United States +5 more locations

TERMINATEDPhase 1/2436 miles

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

NCT01562899

This is a multi-center, open-label, phase Ib/II study. First, the aim of the phase Ib part is to estimate the MTD(s) and/or to identify the recommended phase II dose(s) (RP2D) for the combination of MEK162 and AMG 479 (ganitumab), followed by the phase II part to assess the clinical efficacy and to further assess the safety of the combination in selected patient populations. The dose escalation part of the study will be guided by a Bayesian Logistic Regression Model (BLRM). At least 18 patients are expected to be enrolled in the dose escalation part. Following MTD/ RP2D declaration, patients will be enrolled in three phase II arms to assess efficacy of the combination as well as to better understand the safety, tolerability, PK, antibody concentrations and PD of the combination at MTD/RP2D. Phase II arm 1 will consist of approximately 25 patients with KRAS-mutant colorectal adenocarcinoma. Phase II arm 2 will consist of approximately 20 patients with metastatic pancreatic adenocarcinoma. Phase II arm 3 will consist of approximately 28 patients with mutant BRAFV600 melanoma. Patients will be treated until progression of disease, unacceptable toxicity develops, or withdrawal of informed consent, whichever occurs first. All patients will be followed up - at minimum patients must complete the safety follow-up assessments 30 days after the last dose of the study treatment.

Metastatic Pancreatic AdenocarcinomaBRAF Mutated Melanoma

Pfizer77 participantsStarted Aug 2012

Boston, Massachusetts, United States • Salt Lake City, Utah, United States • Parkville, Victoria, Australia +6 more locations

COMPLETEDPhase 1/2533 miles

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

NCT01271920

The phase Ib part of the trial will assess the MTD of AUY922 in combination with Trastuzumab in patients with Trastuzumab-refractory locally advanced or metastatic HER2+. The MTD is defined as the highest drug dosage not causing in the first cycle of treatment (28 days) medically unacceptable dose limiting toxicity (DLT). The phase II part of the trial will assess any potential effect on efficacy of adding AUY922 to Trastuzumab in patients with Trastuzumab-refractory locally advanced or metastatic HER2+ breast cancer. Both AUY922 and Trastuzumab will be administered as a weekly IV infusion. Treatment should be continued as long as the patient does not have disease progression and tolerates the treatment. The following reasons are examples of acceptable reasons for discontinuing the study; tumor progression (by RECIST, as assessed by the investigator), unacceptable toxicity, death, or discontinuation from the study for any other reason, such as patient refusal, withdrawn consent, lost to follow-up or investigator decision.

Advanced HER2-positive Breast Cancer

Novartis Pharmaceuticals45 participantsStarted Sep 2010

Fayetteville, Arkansas, United States • Dijon, France • Saint-Herblain Cédex, France +13 more locations

COMPLETEDPhase 3588 miles

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162

The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).

Postmenopausal Osteoporosis

Radius Health, Inc.1,139 participantsStarted Nov 2012

Lakewood, Colorado, United States • Hialeah, Florida, United States • Bethesda, Maryland, United States +22 more locations

COMPLETEDNA849 miles

Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema

NCT02245516

The primary objectives of the study are to evaluate the safety and effect of KPI-121 0.25% ophthalmic suspension and KPI-121 1.0% ophthalmic suspension on intraretinal or subretinal fluid secondary to Retinal Vein Occlusion or Diabetic Macular Edema.

Retinal Vein OcclusionDiabetic Macular Edema

Kala Pharmaceuticals, Inc.16 participantsStarted Jul 2014

Beverly Hills, California, United States • Boston, Massachusetts, United States

TERMINATEDPhase 1895 miles

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT03333694

The purpose of this first in human and proof of concept study is to characterize the safety, tolerability and initial efficacy of CLL442 in patients with Squamous Cell Carcinoma in situ (SCCis) to enable further clinical development of CLL442.

Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)

Novartis Pharmaceuticals40 participantsStarted Dec 2017

Phoenix, Arizona, United States • Fountain Valley, California, United States • Gainesville, Florida, United States +5 more locations

COMPLETEDPhase 1986 miles

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

NCT02296853

The primary objective of this study is to evaluate the single-dose pharmacokinetics of tenofovir alafenamide (TAF) and its metabolite tenofovir (TFV) in participants with normal hepatic function and in participants with severe hepatic impairment.

Hepatitis B Virus

Gilead Sciences20 participantsStarted Dec 2014

Miami, Florida, United States • Orlando, Florida, United States • San Antonio, Texas, United States +2 more locations

PreviousPage 450 of 779Next

in Chicago

Heart Diseasein Chicago